{"id":775604,"date":"2023-08-04T12:56:57","date_gmt":"2023-08-04T16:56:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highlights\/"},"modified":"2023-08-04T12:56:57","modified_gmt":"2023-08-04T16:56:57","slug":"achilles-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highlights\/","title":{"rendered":"Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"},"content":{"rendered":"
\n

– Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I\/IIa trials in NSCLC and melanoma –<\/p>\n

–\u00a0\u00a0 neoRanker\u2122\u00a0immunogenicity prediction module of PELEUS\u2122 increases the likelihood of identifying multiple memory T cell responses –<\/p>\n

– Strong cash position of $144 million supports operations through 2025 –
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended June 30, 2023, and recent business highlights.<\/p>\n

\u201cWe look forward to additional clinical data in the fourth quarter of this year from our clonal neoantigen-reactive T cell (cNeT) therapy for the treatment of advanced NSCLC (CHIRON) and metastatic malignant melanoma (THETIS) and are encouraged by the improved manufacturing performance of our VELOS\u2122 Process 2,\u201d said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics<\/strong>. \u201cWe are also very excited about the developments in our AI-driven bioinformatics platform PELEUSTM<\/sup>. PELEUS uses a unique multi-region approach to provide validated and accurate identification of personalized clonal neoantigens. Our newly developed neoRankerTM<\/sup> tool is trained on a proprietary dataset of over 10,000 neoantigens and we calculate that it is potentially twice as good at identifying multiple memory T cell responses than existing deep-learning models. We believe this could be highly differentiated in the design of neoantigen vaccines and further strengthens our leadership position in the field of neoantigen identification.\u201d<\/p>\n

\n Business Highlights<\/strong>\n <\/p>\n